Peptide Stacks for Muscle Growth: What Clinicians Combine, Before and After, What's Legal

Key takeaways

• No peptide stack has ever been tested for muscle growth in a human trial: not CJC-1295 with ipamorelin, not BPC-157 with TB-500, not a secretagogue added to testosterone. The combination that has been tested is growth hormone itself plus testosterone, which is not a stack anyone can legally buy for physique.
• In those trials, growth hormone plus testosterone added more lean mass than either drug alone (4.3 kg versus 0.1 kg on placebo in men over 65 at 26 weeks), strength barely moved, part of the gain was water, and the side effects stacked too: carpal tunnel symptoms in 32% of men on the pair versus none on placebo.
• A stack is only as legal as its least legal component. In October 2026 a US pharmacy can fill sermorelin, tesamorelin (as brand Egrifta only; it cannot be compounded), testosterone (for diagnosed deficiency) and GLP-1 drugs. It cannot legally fill CJC-1295, ipamorelin, MK-677, BPC-157, TB-500, AOD-9604, IGF-1 LR3 or follistatin, whatever a clinic says.
• 'Before and after' for a stack does not exist as data. What exists are single-drug trials: tesamorelin cut visceral fat about 15% over 26 weeks, MK-677 added about 1 kg of fat-free mass in a year with no strength gain, and sermorelin changed hormones but not DEXA scans.
• Stacking growth hormone secretagogues stacks their shared costs (fluid retention, joint pain, tingling hands, higher blood sugar) and multiplies unverified vials. The legal, monitored version is one prescribed drug at a time, with IGF-1 and glucose measured.

Search for the best peptide stack for muscle growth and you get menus: two or three vials, a schedule, a set of photos. This page is about the combinations themselves: what gets put together and why, what evidence exists for any pairing, what the before-and-after data actually measured, and which pieces a licensed US pharmacy can legally dispense. For the compounds one at a time, see our ranking of peptides for muscle growth. For the most common confusion, read are peptides steroids?, and for what goes wrong, side effects of peptides in bodybuilding.

Why people stack peptides

Three ideas sit behind almost every stack.

Two routes to the pituitary. Growth hormone (GH) release is driven by two receptors. GHRH analogs (sermorelin, tesamorelin, CJC-1295) act on the growth hormone-releasing hormone receptor; ghrelin-receptor agonists (ipamorelin, the older GHRPs, and the oral non-peptide MK-677) act on GHS-R1a. Hitting both at once is real physiology: in a laboratory study of young men, a single intravenous dose of natural ghrelin plus GHRH released more GH than either hormone alone, a synergistic effect (Arvat 2001). That experiment, six men, one injection of the natural hormones and three hours of blood sampling, is the scientific basis of the "CJC/ipa" stack. It measured GH in the blood. It did not measure muscle, and nobody has since.

Growth plus repair. A secretagogue for "growth", BPC-157 or TB-500 for "recovery". The repair half has animal data only; the one study of BPC-157 and TB-500 together, in 32 rats with a repaired Achilles tendon, found the combination no better than either peptide alone (Bicer 2026).

Peptides on top of hormones. Clinics add a secretagogue to testosterone therapy. In gyms, the peptides ride alongside anabolic steroids and sometimes insulin: in a study of 92 male recreational bodybuilders in Italy, 43% reported regular hormone use on an anonymous questionnaire, and of those, 95% used anabolic steroids, often with growth hormone (30%) and/or insulin (38%) (Di Girolamo 2024). The real-world "stack" is rarely peptides alone.

What gets combined, and whether a pharmacy can fill it

Legal status below follows our legal tracker as of October 2026. "Can be filled" means a licensed US pharmacy may legally dispense every component.

The rule that decides every row is simple: a stack is only as legal as its least legal component. Under section 503A a pharmacy may compound a peptide only if it has a USP monograph, is a component of an FDA-approved drug or appears on FDA's permitted bulks list. Sermorelin passes; BPC-157, TB-500, CJC-1295, ipamorelin and MK-677 do not. Tesamorelin sits outside these tests: FDA regulates it as a biological product, and biological products cannot be compounded under section 503A or 503B, so the only legal tesamorelin is brand Egrifta. FDA's May 14, 2026 update lists CJC-1295, ipamorelin and AOD-9604 as nominated but withdrawn, which ends their safety flag without giving any basis to compound them, and keeps ibutamoren (MK-677) in Category 2 (FDA categories 2026). BPC-157 and TB-500 were recommended by FDA's advisory committee in July 2026, but no rule has been published, so they remain non-compoundable.

A prescription cannot make a non-compoundable substance compoundable. A clinic that "prescribes" a stack containing any of those is dispensing research vials, and in 2026 FDA told online peptide sellers that a research-use label does not protect a product sold with dosing guides, reconstitution calculators or bundled bacteriostatic water (ArentFox Schiff 2026). Possessing the vials is not a crime; selling them for human use is. Two hormones sit under stricter law: testosterone and other anabolic steroids are Schedule III controlled substances, and distributing growth hormone for anything but an FDA-authorized use is a federal felony (details in are peptides steroids? and the tracker).

What evidence exists for any combination

Stack claims, graded by the evidence behind them

Claim	Grade	What the evidence shows	Sources
A GHRH analog plus a ghrelin-receptor agonist releases more GH than either	C	One intravenous dose of natural ghrelin plus GHRH in 6 young men produced a synergistic GH peak versus either alone. Natural hormones, not CJC-1295 or ipamorelin; GH measured for 3 hours; no outcome measured.	Arvat 2001
Growth hormone plus testosterone adds more lean mass than either alone	B	In men aged 65 to 88 over 26 weeks, lean body mass rose 0.1 kg on placebo, 1.4 kg on testosterone, 3.1 kg on GH and 4.3 kg on both. In men aged 65 to 80 over 6 months, midthigh muscle and aerobic capacity rose only on the combination.	Blackman 2002; Giannoulis 2006
Growth hormone plus testosterone improves strength or performance	C	Strength: marginal (+13.5 kg, P = .05) in older men; 1 of 6 measures in another trial. In 96 recreational athletes over 8 weeks, sprint capacity rose 8.3% on the pair in men, with no change in strength, power or endurance, and the gain was gone 6 weeks after stopping.	Blackman 2002; Giannoulis 2006; Meinhardt 2010
Part of the 'lean mass' gain is water	B	In the athlete trial, GH increased lean body mass through an increase in extracellular water.	Meinhardt 2010
A secretagogue adds to testosterone therapy	D	No trial. A 2020 review of sermorelin, GHRPs, ibutamoren and ipamorelin in hypogonadal men says data on their clinical effects are largely lacking.	Sinha 2020
CJC-1295 plus ipamorelin builds muscle	D	No human trial of the combination for any outcome, and neither molecule has a body-composition trial. The only scientific basis is the single-dose natural-hormone synergy study in the first row.	Arvat 2001
BPC-157 plus TB-500 speeds recovery	D	One rat study (32 rats, Achilles repair): the combination did not confer additional benefit over either agent alone. No human trial.	Bicer 2026
Combining GH-axis drugs adds side effects	B	Carpal tunnel symptoms in 32% of older men on GH plus testosterone versus 0% on placebo; joint pain in 41% on GH; diabetes or glucose intolerance in 18 GH-treated men versus 7 not given GH.	Blackman 2002

The only combination trials with muscle outcomes used somatropin (recombinant growth hormone) plus testosterone. Three are worth knowing.

In the largest, 131 adults aged 65 to 88 were randomized for 26 weeks to growth hormone, sex steroids (testosterone enanthate every two weeks for the men), both, or placebo. In men, lean body mass rose 4.3 kg on the combination against 0.1 kg on placebo, and fat fell; strength did not rise significantly except for a marginal 13.5 kg gain on the combination. The side effects were the cost of admission, and the authors concluded growth hormone interventions in older people should be confined to controlled studies (Blackman 2002). A six-month British trial in 80 men aged 65 to 80, with growth hormone titrated to the upper half of the age range for IGF-1 and a 5 mg testosterone patch, found lean mass rose on growth hormone with or without testosterone, while total fat fell and thigh muscle and aerobic capacity rose only on the combination; one of six strength measures improved (Giannoulis 2006).

The one trial in young, trained people randomized 96 recreational athletes (mean age 28) to eight weeks of growth hormone 2 mg a day, testosterone 250 mg a week, both, or placebo. Growth hormone cut fat and raised lean body mass, but through extracellular water; sprint capacity rose 3.9% overall and 8.3% in men on the combination; strength, jump power and endurance did not change; and the sprint gain disappeared six weeks after the drugs stopped (Meinhardt 2010).

Read together: the pair is additive for lean mass and fat, barely additive for strength, partly water, and additive for side effects. None of it transfers to a peptide stack. No trial has tested a secretagogue with testosterone, and a 2020 review of the idea concluded that the clinical data are largely lacking (Sinha 2020). And somatropin itself cannot legally be distributed for physique.

Before and after: what was actually measured

No stack has a before-and-after trial. There is no controlled measurement, in any group of people, of what CJC-1295 with ipamorelin, a "Wolverine" stack or a secretagogue added to testosterone does to muscle. What exists are single drugs, or growth hormone plus testosterone, measured at fixed points.

Doses in this table are the ones the trials used, reported so you can judge claims, not to be copied; the growth hormone and high-dose testosterone arms are not legal prescriptions for physique. Three timing lessons come out of it. Growth hormone's early "lean mass" is partly water, so a fuller look in the first weeks is not muscle. Fat changes worth photographing took months in the tesamorelin trials. And in the only trial that checked, the performance gain was gone six weeks after stopping.

Before-and-after photos of stacks are a different genre. They are uncontrolled, they mix lighting, pump, diet and dehydration, many are taken during an anabolic steroid cycle, and nobody knows what was in the vials. We do not publish any, and a clinic gallery is marketing, not a result.

Muscle growth and fat loss: the honest pairing

The "and fat loss" half of the search has better answers than the muscle half, and none of them is a stack. The peptides with large fat-loss trials are the GLP-1 drugs (see best peptides for weight loss) and, for visceral fat specifically, tesamorelin. AOD-9604, sold as the fat-burning add-on, cannot be compounded. No trial has paired a GLP-1 with a secretagogue to protect muscle. The variable that mattered in the muscle trials was training: in the testosterone benchmark, men who lifted gained far more than men who did not (Bhasin 1996).

Risks that come from combining

The side effects of each compound are on our bodybuilding side-effects page; stacking adds four problems.

1. Shared mechanism, added effects. Every secretagogue raises GH and IGF-1, so two of them add the same costs: fluid retention, joint pain, tingling hands, carpal tunnel. In the growth hormone plus testosterone trial, carpal tunnel symptoms affected 32% of men on the pair (Blackman 2002).
2. Glucose. Growth hormone raised diabetes or glucose intolerance (18 men on GH versus 7 not on it) (Blackman 2002), and MK-677 raised fasting glucose by about 5 mg/dL and lowered insulin sensitivity (Nass 2008). Stacking them, or adding insulin as some bodybuilders do, moves glucose in both directions at once.
3. No mixing data. Nobody has studied two peptides in one vial or syringe; our mixing compatibility chart explains why the only legitimate combinations are the ones a pharmacy prepares and labels.
4. More unverified vials. Each research vial is its own sterility and dosing gamble, and stacks double or triple the injections.

Athletes should also know that every secretagogue in these stacks, and BPC-157 and TB-500 as well, is prohibited in tested sport; are peptides steroids? has the anti-doping classes.

How to judge a clinic's stack

• Ask the pharmacy question for every vial. Which pharmacy, in which state, and on what 503A basis? For CJC-1295, ipamorelin, MK-677, BPC-157, TB-500, AOD-9604 or IGF-1 LR3, there is no honest answer.
• Ask what will be measured. IGF-1 and fasting glucose or HbA1c at baseline and again at 8 to 12 weeks, as our sermorelin profile describes. A stack with no labs is a stack with no monitoring.
• Ask how testosterone was justified. Two low morning levels plus symptoms, or a questionnaire?
• Walk away from promises. Any program that promises pounds of muscle, sells "blends" or shows a before-and-after gallery is selling the genre above.

The legal version, and what it costs

The legitimate version of a "muscle stack" in 2026 is usually one drug at a time, chosen for a diagnosis, with labs before and after. Prices are from our cost guide, collected October 9, 2026.

If a clinician prescribes a peptide, the pharmacy label gives the concentration and our peptide calculator converts it to syringe units. Our guides to who qualifies for peptide therapy, getting peptides prescribed online and the peptide therapy complete guide cover the evaluation; best online peptide clinics compares providers on the same terms.

Bottom line

The best peptide stack for muscle growth, judged by evidence, does not exist yet: no combination of peptides has been tested for muscle in people. The pairing that has been tested, growth hormone plus testosterone, adds lean mass (partly water), barely adds strength, and stacks the side effects, and it is not legally available for physique. Most stacks sold in 2026 contain at least one component no US pharmacy may fill, which makes the whole stack a research-vial product. If a clinician finds low testosterone or a low IGF-1, the legal options are single, prescribed and monitored. Everything else is an experiment without a control group.

Frequently asked questions

+−What is the best peptide stack for muscle growth?

There is no evidence-based answer, because no peptide stack has been tested for muscle growth in a human trial. CJC-1295 with ipamorelin, BPC-157 with TB-500 and a secretagogue added to testosterone have never been studied as combinations. The only combination with muscle data is growth hormone itself plus testosterone, which added more lean mass than either alone in trials, with little strength gain and more side effects, and growth hormone cannot legally be distributed for physique. The compound with strong muscle evidence on its own is testosterone, which is not a peptide and is prescribed only for diagnosed deficiency.

+−What is the best peptide stack for muscle growth and fat loss?

Nothing has been tested as a stack for both. The peptides with strong fat-loss evidence are the GLP-1 drugs, which are not muscle builders, and tesamorelin, which cut visceral fat by about 15 percent over 26 weeks in people with HIV-associated abdominal fat. No trial has paired a GLP-1 with a growth hormone secretagogue. AOD-9604, often sold as the fat-loss half of a stack, was voted down 0 to 12 by FDA's advisory committee and cannot be compounded.

+−Can you stack peptides with testosterone?

Clinics commonly prescribe sermorelin or tesamorelin to men on testosterone therapy, and there is no documented interaction, but no trial has tested a secretagogue with testosterone for muscle; a 2020 review says the clinical data are largely lacking. Trials of growth hormone itself plus testosterone found more lean mass than either alone, marginal strength gains and more carpal tunnel symptoms and glucose problems. Testosterone is a Schedule III controlled substance prescribed for diagnosed hypogonadism, so the legal version of this pairing starts with two low morning testosterone levels and symptoms.

+−Can you stack tesamorelin and sermorelin?

A clinician can legally prescribe both, sermorelin as a compounded drug and tesamorelin only as the brand Egrifta, which cannot be compounded because FDA regulates it as a biological product. There is no trial of the pair, and both act on the same GHRH receptor on the pituitary, so stacking them adds exposure and cost without adding a second mechanism. If a GHRH analog is reasonable for you, the usual choice is one or the other: tesamorelin when visceral fat is the problem, sermorelin for a lower-cost nudge to growth hormone output, with IGF-1 measured before and after.

+−How many peptides can you stack at once?

No study has defined a safe number, because no combination of research peptides has been studied at all. Each added injectable adds its own unknowns, and when the compounds share a mechanism, as growth hormone secretagogues do, their side effects add up: fluid retention, joint pain, tingling hands and higher blood sugar. Each added research vial also adds an unverified product. A monitored prescription of one drug is a different proposition from a multi-vial stack.

+−What peptides should not be stacked together?

There is no evidence-based list, because the combinations have not been studied. The combinations most worth avoiding are two or more growth hormone secretagogues, any secretagogue with MK-677 in someone with high blood sugar, anything stacked with insulin or IGF-1, which can both cause dangerous low blood sugar, and any growth-promoting stack in someone with a cancer history. Mixing peptides in one syringe has no compatibility data either.

+−Are there real before-and-after results for peptide stacks?

No. No stack has a controlled before-and-after measurement in a group of people. The measured changes that exist belong to single drugs: tesamorelin reduced visceral fat by about 15 percent over 26 weeks, MK-677 added about 1 kg of fat-free mass in a year with no strength gain, and sermorelin at 2 mg nightly for six weeks did not change DEXA body composition. Photos online are uncontrolled, often taken alongside anabolic steroids, and of vials no one tested.

+−Is it legal for a clinic to prescribe a peptide stack?

Only if every component can be legally dispensed. As of October 2026 a licensed US pharmacy may compound sermorelin and dispense brand tesamorelin (Egrifta, which cannot be compounded), and testosterone and GLP-1 drugs are approved products. CJC-1295, ipamorelin, MK-677, BPC-157, TB-500, AOD-9604, IGF-1 LR3 and follistatin cannot be legally filled by any US pharmacy, and a prescription does not change that. A clinic that sells a stack containing them is dispensing research vials, whatever it calls them.

Sources

1. StudyBhasin S et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996;335:1-7. (1996)
2. StudyArvat E et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab 2001;86:1169-74. (2001)
3. StudyBlackman MR et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 2002;288:2282-92. (2002)
4. StudyGiannoulis MG et al. The effects of growth hormone and/or testosterone in healthy elderly men: a randomized controlled trial. J Clin Endocrinol Metab 2006;91:477-84. (2006)
5. StudyMeinhardt U et al. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Ann Intern Med 2010;152:568-77. (2010)
6. StudyRudman D et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6. (1990)
7. ReviewLiu H et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007;146:104-15. (2007)
8. StudyNass R et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008;149:601-11. (2008)
9. StudyVittone J et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997;46:89-96. (1997)
10. StudyFalutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010;95:4291-304. (2010)
11. ReviewSinha DK et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol 2020;9(Suppl 2):S149-59. (2020)
12. StudyBicer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg 2026;37:822-37. (2026)
13. StudyDi Girolamo FG et al. Metabolic consequences of anabolic steroids, insulin, and growth hormone abuse in recreational bodybuilders: implications for the World Anti-Doping Agency passport. Sports Med Open 2024;10:28. (2024)
14. RegulatoryFDA. Bulk drug substances nominated for use in compounding under section 503A: Category 1, 2 and 3 lists and updates (updated May 14, 2026). (2026)
15. NewsArentFox Schiff. RUO-ined: five peptide vendors learn that research use only is not a legal strategy (FDA warning letters of August 24, 2026). September 18, 2026. (2026)